Incyte Ingenuity Award for graft versus host disease

Incyte, a global biopharmaceutical company announces its opening call for submissions for its new Incyte Ingenuity Award. a program created to support people living with graft-versus-host disease (GVHD), as well as their caregivers and physicians.  GVHD is a potentially life-threatening condition that can occur after a stem cell or bone marrow transplant from a donor initiate an immune response and attack the transplant recipient’s organs. Here to talk about Incyte’s dedication to the program is Incyte’s Executive Vice President, General Manager, United States, Dr. Barry Flannelly.  The program is expected to fund up to $100,000 a year for one innovative program or idea.

Read More

SyTrue, Inc., NLP OS™ Platform

Kyle Silvestro, CEO of the healthcare software company SyTrue, Inc., discusses SyTrue’s Natural Language Processing (NLP) Operating System (OS) NLP OS™ and how they are offering their services for free for COVID-19 studies. He also talks about SyTrue’s partnering with Microsoft.

Read More

Genomic Medicines – Sangamo Therapeutics Inc

Dr. Bettina Cockroft, M.D., SVP and CMO at Sangamo Therapeutics, Inc., a genomic medicine company, discusses their approach to treating disease and why genomic medicines are so important to the future of medicine.  She also talks about one of the latest therapies Sangamo has in a Phase 1/2 clinical trial for the treatment of Fabry disease, a rare, X-linked lysosomal storage disorder caused by a gene mutation in an enzyme responsible for breaking down fatty substances.

Read More

Electronic Health Record (EHR) heart risk calculator

Dr. Ankit Shah, a leading cardiologist with MedStar Health in Baltimore, MD, discusses a promising new tool, an interactive heart risk calculator that will help patients get a quicker and more personal assessment of their risk for heart disease, stroke, and other cardiovascular diseases. MedStar Health patients for the first time will see their heart health information embedded in their electronic health records (EHRs) using an easy-to-read, interactive interface.  It will quickly show patients the impact that their current blood pressure, cholesterol and other risk factors play in their risk of heart disease or stroke.

Read More

Gloucester Marine Genomics Institute Biotechnology Training

The Gloucester Marine Genomics Institute (GMGI) in Gloucester, Massachusetts has recently received Workforce Skills Capital Grants to expand its facilities and purchase biomanufacturing equipment in order to train an even bigger group of Academy students for careers in biotechnology, an industry that is desperate for talent / trained professionals.  Here to talk about this news and the future of training top biotechnology workers to meet the industry’s ever-growing demand is Chief Operating Officer Chris Bolzan.

Read More

Talking openly about brain health

Michelle Dickinson, Author, TED Speaker, and advocate, discusses ways to decrease the mental health stigma and shame that prevents people from accessing care, why we should invest in mental health or brain health in the workplace and her own personal story of perseverance and triumph.

Read More

Vedolizumab (Entyvio®) trial results for crohn’s disease

Dr. Asit Parikh, MD, SVP, and head of the Gastrointestinal Therapeutic Area at Takeda Pharmaceutical Company Limited discusses new data presented at the 15th Congress of the European Crohn’s and Colitis Organisation (ECCO) from the phase 3 VISIBLE 2 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of vedolizumab (Entyvio®) for use during maintenance therapy in adult patients with moderately to severely active Crohn’s disease (CD).

Read More

Colorectal cancer screening study

Dr. Paul Limburg, a gastroenterology consultant at the Mayo Clinic, and CMO for screening at Exact Sciences, and co-author of this study discusses the results of the colorectal cancer screening study published in the Journal of Medical Screening.  The study indicated high adherence to getting screened with the at-home, stool-based, multi-target DNA test. These findings point to the importance of choice in colorectal cancer (CRC) screening options, as well as the role of patient navigation programs to help with adherence, at a time when 1-in-3 individuals are not up to date on CRC screening.

Read More